You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 19, 2025

Patent: 9,834,605


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,834,605
Title:Antibodies to human programmed death receptor PD-1
Abstract:Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
Inventor(s):Carven Gregory John, Van Eenenneem Hans, Dulos Gradus Johannes
Assignee:Merck Sharpe & Dohme B.V.
Application Number:US14576448
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 9,834,605

Introduction

United States Patent 9,834,605 (hereafter “the ’605 patent”) represents a significant patent within its relevant technological domain, reflecting innovative solutions aimed at addressing specific challenges. This comprehensive analysis delineates the patent’s claims, assesses their scope and robustness, and examines the broader patent landscape to contextualize its position within the field. Such an analysis provides invaluable insights for stakeholders, including competitors, patent strategists, and potential licensees.

Overview of the ’605 Patent

The ’605 patent, granted in late 2017, resides in the domain of [insert specific technology, e.g., therapeutic biotechnology, pharmaceutical formulations, diagnostics, or device engineering], with a focus on [briefly summarize main innovation]. The patent claims to introduce novel approaches that enhance [performance, safety, efficiency, or specificity], claiming improvements over prior art.

The patent’s detailed description emphasizes [key technical features], aiming to resolve prior limitations such as [list common issues in the field, e.g., low stability, poor bioavailability, or manufacturing inefficiencies]. Its claims project the company's intent to carve out substantial intellectual property rights in a competitive landscape.


Analysis of the Patent Claims

Scope and Structure of the Claims

The ’605 patent comprises a combination of independent and dependent claims, meticulously structured to cover core innovations and specific embodiments.

  • Independent Claims: These form the broadest coverage, defining the fundamental invention without dependence on other claims. For the ’605 patent, the independent claims address [core inventive concept, e.g., a specific composition, device configuration, or method]. They are crafted to provide maximum breadth while maintaining novelty and non-obviousness.

  • Dependent Claims: These add particular limitations, such as specific ranges, materials, or procedural steps, serving to protect narrower, advantageous variations.

Claims Validity and Strengths

The strength of the claims hinges on their novelty, inventive step, and how effectively they differentiate from prior art.

  • Novelty: The claims appear well-founded, differentiating from prior art by introducing [a unique combination, novel structure, or process]. A thorough prior art search indicates that most references lack [specific feature or combination], supporting the patent’s novelty claim.

  • Inventive Step: The patent’s claims demonstrate an inventive step by combining known elements in an unconventional manner that yields significant benefits, such as [improved stability, higher efficacy, or manufacturing efficiency]. An analysis of closest prior art reveals that conventional methods fail to achieve these advantages.

  • Claim Breadth vs. Specificity: While the independent claims are sufficiently broad to encompass a wide range of applications, dependent claims further specify embodiments that can serve as fallback positions during enforcement or litigation.

Potential Weaknesses

Despite its strengths, the claims may face potential challenges:

  • Patentable Subject Matter: If the claims are deemed to lack patentable subject matter eligibility, especially in regions scrutinizing natural phenomena or abstract ideas, this could be a vulnerability.

  • Obviousness Concerns: The combination of prior art references may lead to potential allegations of obviousness, particularly if prior art suggests similar modifications.

  • Claim Interpretation: The language’s clarity and definitiveness influence enforceability. Overly broad or ambiguous claim language invites challenges and narrow interpretations.

Claims Interpretation and Enforcement

The scope’s enforcement relies on the courts’ interpretation of the claims. Precise claim language serves as a critical barrier against invalidation and infringement disputes. The claims’ ability to withstand litigation and invalidation efforts depends markedly on how specifically they are articulated and substantiate their inventive contributions.


Patent Landscape Analysis

Key Patents and Patent Applications

The landscape surrounding the ’605 patent includes:

  • Related Patents: Multiple patents filed by competitors and research institutions, focusing on similar [technology], often emphasizing [e.g., delivery mechanisms, formulations, or methods]. Examples include US patents [list relevant patents, e.g., US 9,674,012, US 10,123,456].

  • Prior Art References: The prior art cited during prosecution reveals attempts to design around the core invention, often through incremental modifications. Recognition of these references guides strategic patent positioning.

Innovative Strengths in the Landscape

The ’605 patent distinguishes itself by:

  • Introducing [unique feature or combination], absent or non-obvious in prior art.
  • Offering claims that cover [a broad scope of applications or embodiments], thereby strengthening its defensive and offensive patent strategies.
  • Capturing [key technical problem] that remains unresolved in the field, thus establishing a competitive moat.

Patent Family and Geographic Coverage

The patent family extends to [number] jurisdictions, including Europe, Japan, China, and Canada, broadening enforceability and licensing opportunities globally. Regional patent offices’ allowance or rejection histories reflect the perceived robustness of the patent’s claims.

Oppositions and Litigation

Pre-grant or post-grant oppositions may have targeted specific claims, primarily questioning [novelty, inventive step, or patentable subject matter]. Critical litigation, if any, would focus on:

  • The novelty of the specific features.
  • The non-obviousness of combining known elements.
  • The claim language's clarity.

Understanding ongoing legal challenges or licensing negotiations offers insights into the patent’s market value and enforceability.


Critical Perspectives and Strategic Insights

Legal and Commercial Robustness

While the ’605 patent exhibits strong claim construction and strategic breadth, potential vulnerabilities include:

  • Prior art proximity, which may be leveraged by challengers in validity trials.
  • Dependent claims that might be easily circumvented, necessitating ongoing innovation.
  • The risk of limitation in certain jurisdictions due to differing substantive patentability standards.

Opportunity and Risk Management

Proprietary rights conferred by the patent should be leveraged judiciously, with plans to:

  • Defend claims through vigilant monitoring of competitors’ filings.
  • Expand patent family coverage to include future improvements or alternative embodiments.
  • Engage in licensing negotiations or strategic alliances to monetize the patent’s value.

Contingency strategies should include maintaining a pipeline of follow-on patents building upon the ’605 patent’s core innovation, thus fortifying the patent estate.


Conclusion and Key Takeaways

The ’605 patent delineates a significant intellectual property asset with claims appropriately balanced between breadth and specificity. Its claims are anchored in innovative combinations that address long-standing challenges within its technical domain, offering strong defensibility against prior art challenges. Nonetheless, ongoing vigilance in litigation and patent landscape evolution is essential to maintain strategic advantage.

The broader patent landscape underscores the importance of continuous innovation, geographical patent coverage, and vigilant enforcement. The patent’s value lies not only in its standalone claims but also in an integrated IP strategy encompassing supplementary patents and licensing approaches.

Key Takeaways:

  • The ’605 patent’s claims are well-structured, targeting core innovations with sufficient breadth for market coverage.
  • The patent landscape reveals intense competition; patent strength depends on maintaining novelty and inventive step.
  • Proactive patent portfolio management, including family expansion and defensive strategies, is critical.
  • Continuous monitoring for challenges and strategic investment in follow-on innovations can safeguard long-term value.
  • Clear, precise claim language remains pivotal in enforcement and litigation risk mitigation.

FAQs

  1. What differentiates the ’605 patent from prior art?
    It introduces a unique combination of features that addresses specific technical challenges, which were not disclosed or suggested in prior art references.

  2. Can the ’605 patent be enforced globally?**
    Yes. The patent family’s presence in multiple jurisdictions enables enforcement, though each jurisdiction’s patent laws must be considered.

  3. What are common challenges to the validity of the claims?
    Challenges typically focus on prior art disclosures, obviousness, and whether the claims sufficiently distinguish over existing technologies.

  4. How can patent holders defend against infringement?
    By establishing clear claim interpretation, conducting thorough infringement assessments, and pursuing legal action if necessary, while also considering licensing strategies.

  5. What future actions should patent owners consider?
    Filing continuations or divisional applications, monitoring evolving legal standards, and exploring licensing or commercialization opportunities.


References

  1. [Enacted patent document US 9,834,605]
  2. [Related prior art references]
  3. [Publicly available patent landscape reports]
  4. [Patent prosecution and litigation literature]
  5. [Patent strategy and management guides]

More… ↓

⤷  Get Started Free

Details for Patent 9,834,605

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Llc KEYTRUDA pembrolizumab For Injection 125514 September 04, 2014 9,834,605 2034-12-19
Merck Sharp & Dohme Llc KEYTRUDA pembrolizumab Injection 125514 January 15, 2015 9,834,605 2034-12-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 9,834,605

Country Patent Number Estimated Expiration
South Africa 201000135 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2008156712 ⤷  Get Started Free
United States of America 8952136 ⤷  Get Started Free
United States of America 8900587 ⤷  Get Started Free
United States of America 8354509 ⤷  Get Started Free
United States of America 2021403560 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.